OJEMDA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OJEMDA (OJEMDA).
OJEMDA is a selective inhibitor of tropomyosin receptor kinases (TrkA, TrkB, TrkC), blocking neurotrophin signaling and inducing apoptosis in TRK fusion-positive tumors.
| Metabolism | OJEMDA is metabolized primarily by CYP3A4 and CYP2C8, with minor contributions from CYP2D6 and CYP2C9. |
| Excretion | Primarily hepatic metabolism; <5% excreted unchanged in urine; biliary/fecal excretion of metabolites accounts for >80% of total clearance. |
| Half-life | Terminal half-life is 12-15 hours in adults; 18-24 hours in pediatric patients; supports once-daily dosing. |
| Protein binding | 99.7% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 2.6 L/kg, indicating extensive extravascular distribution beyond plasma volume. |
| Bioavailability | Oral bioavailability is 45% (range 30-60%) with high-fat meal increasing AUC by 1.5-fold. |
| Onset of Action | Oral: 1-2 hours to achieve therapeutic plasma concentrations; peak effect on tumor growth inhibition observed within 2 weeks. |
| Duration of Action | 24 hours with once-daily dosing; continuous dosing required for sustained target inhibition; clinical effect duration correlates with trough concentrations above IC90. |
4 mg orally once daily. Continue until disease progression or unacceptable toxicity.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (CrCl ≥30 mL/min). Not studied in severe renal impairment (CrCl <30 mL/min). |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose to 2 mg orally once daily. Child-Pugh Class C: Not recommended. |
| Pediatric use | Not approved for use in pediatric patients. |
| Geriatric use | No specific dose adjustment required based on age alone. Monitor for adverse events due to potential age-related comorbidities. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for OJEMDA (OJEMDA).
| Breastfeeding | No data on presence in human milk; M/P ratio unknown. Because of potential for serious adverse reactions in breastfed infants (e.g., diarrhea, skin reactions), advise women not to breastfeed during treatment and for 3 weeks after last dose. |
| Teratogenic Risk | Fetal risks in first trimester: Based on mechanism of action (EGFR inhibitor), there is potential for teratogenicity; animal studies show embryo-fetal mortality and malformations at clinically relevant exposures. Second and third trimester: Risk of fetal growth restriction, oligohydramnios, and potential for impaired renal function. |
■ FDA Black Box Warning
None.
| Serious Effects |
["None."]
| Precautions | ["Hepatotoxicity: Elevations of aminotransferases and bilirubin have occurred. Monitor liver function tests before and during treatment.","Fetal toxicity: Can cause fetal harm. Advise patients of reproductive potential to use effective contraception.","Fertility impairment: May impair fertility in females of reproductive potential.","Tumor lysis syndrome: Reported; ensure adequate hydration and monitor electrolytes.","Drug-drug interactions: Avoid strong CYP3A4 inducers and inhibitors; adjust dose with moderate CYP3A4 inhibitors."] |
Loading safety data…
| Fetal Monitoring | Monitor complete blood count, liver function, and serum creatinine monthly; assess blood pressure; fetal ultrasound for growth and amniotic fluid volume every 4 weeks once pregnancy is continued. |
| Fertility Effects | In animal studies, impaired fertility with reduced mating indices and decreased ovarian weights. Human data are lacking; may cause reversible or irreversible impairment of male and female fertility (oligospermia, anovulation). |